-
Something wrong with this record ?
Linked magnolol dimer as a selective PPARγ agonist - Structure-based rational design, synthesis, and bioactivity evaluation
D. Dreier, S. Latkolik, L. Rycek, M. Schnürch, A. Dymáková, AG. Atanasov, A. Ladurner, EH. Heiss, H. Stuppner, D. Schuster, MD. Mihovilovic, VM. Dirsch,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2011
Nature Open Access
from 2011-12-01
PubMed Central
from 2011
Europe PubMed Central
from 2011
ProQuest Central
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Health & Medicine (ProQuest)
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
Springer Nature OA/Free Journals
from 2011-12-01
- MeSH
- Biphenyl Compounds chemical synthesis chemistry pharmacology MeSH
- Dimerization * MeSH
- HEK293 Cells MeSH
- Humans MeSH
- Ligands MeSH
- Lignans chemical synthesis chemistry pharmacology MeSH
- Pioglitazone pharmacology MeSH
- PPAR gamma agonists chemistry metabolism MeSH
- Protein Domains MeSH
- Drug Design * MeSH
- Retinoid X Receptor alpha metabolism MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The nuclear receptors peroxisome proliferator-activated receptor γ (PPARγ) and its hetero-dimerization partner retinoid X receptor α (RXRα) are considered as drug targets in the treatment of diseases like the metabolic syndrome and diabetes mellitus type 2. Effort has been made to develop new agonists for PPARγ to obtain ligands with more favorable properties than currently used drugs. Magnolol was previously described as dual agonist of PPARγ and RXRα. Here we show the structure-based rational design of a linked magnolol dimer within the ligand binding domain of PPARγ and its synthesis. Furthermore, we evaluated its binding properties and functionality as a PPARγ agonist in vitro with the purified PPARγ ligand binding domain (LBD) and in a cell-based nuclear receptor transactivation model in HEK293 cells. We determined the synthesized magnolol dimer to bind with much higher affinity to the purified PPARγ ligand binding domain than magnolol (K i values of 5.03 and 64.42 nM, respectively). Regarding their potency to transactivate a PPARγ-dependent luciferase gene both compounds were equally effective. This is likely due to the PPARγ specificity of the newly designed magnolol dimer and lack of RXRα-driven transactivation activity by this dimeric compound.
Department of Pharmacognosy University of Vienna Vienna Austria
Institute of Applied Synthetic Chemistry TU Wien Vienna Austria
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028713
- 003
- CZ-PrNML
- 005
- 20190816112414.0
- 007
- ta
- 008
- 190813s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-017-12628-5 $2 doi
- 035 __
- $a (PubMed)29057944
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Dreier, Dominik $u Institute of Applied Synthetic Chemistry, TU Wien, Vienna, Austria.
- 245 10
- $a Linked magnolol dimer as a selective PPARγ agonist - Structure-based rational design, synthesis, and bioactivity evaluation / $c D. Dreier, S. Latkolik, L. Rycek, M. Schnürch, A. Dymáková, AG. Atanasov, A. Ladurner, EH. Heiss, H. Stuppner, D. Schuster, MD. Mihovilovic, VM. Dirsch,
- 520 9_
- $a The nuclear receptors peroxisome proliferator-activated receptor γ (PPARγ) and its hetero-dimerization partner retinoid X receptor α (RXRα) are considered as drug targets in the treatment of diseases like the metabolic syndrome and diabetes mellitus type 2. Effort has been made to develop new agonists for PPARγ to obtain ligands with more favorable properties than currently used drugs. Magnolol was previously described as dual agonist of PPARγ and RXRα. Here we show the structure-based rational design of a linked magnolol dimer within the ligand binding domain of PPARγ and its synthesis. Furthermore, we evaluated its binding properties and functionality as a PPARγ agonist in vitro with the purified PPARγ ligand binding domain (LBD) and in a cell-based nuclear receptor transactivation model in HEK293 cells. We determined the synthesized magnolol dimer to bind with much higher affinity to the purified PPARγ ligand binding domain than magnolol (K i values of 5.03 and 64.42 nM, respectively). Regarding their potency to transactivate a PPARγ-dependent luciferase gene both compounds were equally effective. This is likely due to the PPARγ specificity of the newly designed magnolol dimer and lack of RXRα-driven transactivation activity by this dimeric compound.
- 650 _2
- $a bifenylové sloučeniny $x chemická syntéza $x chemie $x farmakologie $7 D001713
- 650 12
- $a dimerizace $7 D019281
- 650 12
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a HEK293 buňky $7 D057809
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ligandy $7 D008024
- 650 _2
- $a lignany $x chemická syntéza $x chemie $x farmakologie $7 D017705
- 650 _2
- $a PPAR gama $x agonisté $x chemie $x metabolismus $7 D047495
- 650 _2
- $a pioglitazon $x farmakologie $7 D000077205
- 650 _2
- $a proteinové domény $7 D000072417
- 650 _2
- $a retinoidní X receptor alfa $x metabolismus $7 D047490
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Latkolik, Simone $u Department of Pharmacognosy, University of Vienna, Vienna, Austria.
- 700 1_
- $a Rycek, Lukas $u Institute of Applied Synthetic Chemistry, TU Wien, Vienna, Austria.
- 700 1_
- $a Schnürch, Michael $u Institute of Applied Synthetic Chemistry, TU Wien, Vienna, Austria.
- 700 1_
- $a Dymáková, Andrea $u Department of Pharmacognosy, University of Vienna, Vienna, Austria. Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
- 700 1_
- $a Atanasov, Atanas G $u Department of Pharmacognosy, University of Vienna, Vienna, Austria. Institute of Genetics and Animal Breeding of the Polish Academy of Sciences, Jastrzebiec, Poland.
- 700 1_
- $a Ladurner, Angela $u Department of Pharmacognosy, University of Vienna, Vienna, Austria.
- 700 1_
- $a Heiss, Elke H $u Department of Pharmacognosy, University of Vienna, Vienna, Austria.
- 700 1_
- $a Stuppner, Hermann $u Institute of Pharmacy/Pharmacognosy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck, Austria.
- 700 1_
- $a Schuster, Daniela $u Institute of Pharmacy/Pharmaceutical Chemistry and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck, Austria. Daniela.Schuster@uibk.ac.at.
- 700 1_
- $a Mihovilovic, Marko D $u Institute of Applied Synthetic Chemistry, TU Wien, Vienna, Austria.
- 700 1_
- $a Dirsch, Verena M $u Department of Pharmacognosy, University of Vienna, Vienna, Austria. Verena.Dirsch@univie.ac.at.
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 7, č. 1 (2017), s. 13002
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29057944 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190816112644 $b ABA008
- 999 __
- $a ok $b bmc $g 1433862 $s 1067173
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 7 $c 1 $d 13002 $e 20171020 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- LZP __
- $a Pubmed-20190813